Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 4/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29631092 | 1.00 | GAA (0.34) | GAALPLLIPGUCHL1LIPE | |
| Hydrochloric Acid SCHEMBL21840736 | 0.98 | GAA (0.33) | GAALPLLIPGUCHL1LIPE | |
| SCHEMBL163933 | 0.86 | GAA (0.38) | GAALPLLIPGUCHL1F11 | |
| SCHEMBL29515710 | 0.80 | LPL (0.34) | LPLLIPGUCHL1F11P2RX7 | |
| SCHEMBL2352761 | 0.80 | LPL (0.34) | LPLLIPGUCHL1F11P2RX7 | |
| SCHEMBL29778045 | 0.79 | GAA (0.33) | GAAEGFR | |
| SCHEMBL12327195 | 0.79 | LPL (0.40) | LPLLIPGF11JAK2BTK | |
| SCHEMBL18356426 | 0.79 | LPL (0.33) | LPLLIPGF11P2RX7 | |
| SCHEMBL31069967 | 0.79 | GAA (0.38) | GAALPLLIPGF11 | |
| SCHEMBL28990805 | 0.79 | F11 (0.34) | LPLLIPGUCHL1F11P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108521-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2026-04-23 | — | — | US | disclosed |
| WO-2024159094-A1 | PYRIMIDINYL (HETERO)AROMATIC AMINOPYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES | ENLIVEN INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024073871-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-04-11 | — | — | WO | disclosed |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | 858 THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020517-A1 | 3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER | 858 THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| CN-109563094-B | (hetero) aryl-substituted piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-03-18 | — | — | CN | disclosed |
| EP-3397627-B1 | INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2022-01-26 | — | — | EP | disclosed |
| EP-2300475-A1 | DIAZACARBAZOLES AND METHODS OF USE | Genentech, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2009151598-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008076046-A1 | NOVEL 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076044-A1 | NOVEL 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146597-A1 | Therapeutic Tetrahydroisoquinoline-Based Compositions for Cancer Therapy | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146597-A1 | Therapeutic Tetrahydroisoquinoline-Based Compositions for Cancer Therapy | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008064329-A1 | THERAPEUTIC TETRAHYDROISOQUINOLINE-BASED COMPOSITIONS FOR CANCER THERAPY | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146597-A1 | Therapeutic Tetrahydroisoquinoline-Based Compositions for Cancer Therapy | TP53, MCL1, HRAS | GAA 1871/4885LPL 3508/4885LIPG 1721/4885 |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | GAA 807/4885LPL 2583/4885LIPG 1744/4885 |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | BACE1, BACE2, PSEN1 | GAA 91/4885LPL 3532/4885LIPG 3895/4885 |
| US-20260108521-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | GHSR, GSPT1, GLRA1 | GAA 1275/4885LPL 2951/4885LIPG 4240/4885 |
| US-20240101544-A1 | INHIBITORS OF QPCTL AND QPCT | ACAT1, ACAT2, LCAT | GAA 210/4885LPL 502/4885LIPG 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.